Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation:

Rodríguez-Sánchez, L. (Lara); Emberton, M. (Mark); de Reijke, T. (Theo); et al. "Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer". The World Journal of Men's Health. 41, 2023, e80

Abstract

Prostate cancer (PCa) is a disease that exhibits het- erogeneity in terms of its clinical behavior [1]. There- fore, it is not surprising that heterogeneity also affects the way we treat PCa. Radical treatments such as radical prostatectomy (RP) and radiation therapy (RT) have for years been consid- ered the standard of care for most men with non-meta- static PCa [2,3]. During the last 120 years, many changes regarding surgical and radiation techniques have arose to reduce morbidity and improve oncological and func- tional outcomes [4]. However, despite all of the effort behind these advances, the negative effects on sexual, urinary and bowel function remain unsolved [5].

URI:

https://hdl.handle.net/10171/68906

DOI:

10.5534/wjmh.230160

Appears in Collections:

DA - CUN - Urología - Artículos de revista

Files in This Item: